Affimed N.V
General information
Affimed N.V
Im Neuenheimer Feld 582
Technologiepark
69120 Heidelberg, Baden-Württemberg
Germany
Contact person: Andreas Harstrick, Interim Chief Executive Officer. Chief Medical Off
Company main phone: +49 (6221) 674360
Company main fax: +49 (6221) 6743649
Website: https://www.affimed.com
Im Neuenheimer Feld 582
Technologiepark
69120 Heidelberg, Baden-Württemberg
Germany
Contact person: Andreas Harstrick, Interim Chief Executive Officer. Chief Medical Off
Company main phone: +49 (6221) 674360
Company main fax: +49 (6221) 6743649
Website: https://www.affimed.com
| Year founded: | 2000 |
| Source of foundation: | Spin-off from public institution / NPO |
| Name of foundation source: | German Cancer Research Centre (DKFZ) |
| No. of employees: |
Worldwide: 76 |
Corporate description / mission:
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells.
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2014
Headquarters: HQ: Yes
IPO (year): 2014
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 4 | |
| Phase I: | 2 | |
| Phase II: | 6 |
Description of products:
AFM13
AFM24
AFM28
AFM32, etc.
AFM13
AFM24
AFM28
AFM32, etc.
Technology used:
ROCK® Platform
ROCK® Platform
Financing details
Fiscal year (end of) 2023
| Revenues: | USD 8.95M | |
| R&D expenses: | USD 102.74M | |
| Cash: | USD 41.69M |
| Total liabilities: | USD 42.58M | |
| No. of shares: | 15'227'500 | |
| Market cap. / valuation: | USD 78.42M |
Collaborations & Clients
Partnering strategy / collaborations:
Genentech
Artiva
Roche
Merck, etc.
Genentech
Artiva
Roche
Merck, etc.
© 2024 Biotechgate by Venture Valuation